

0h
24h
Dilution
1000000
100000
10000
1000
100
10
1
Virus+DPBS
Virus+MAPA
Virus+MAA
Virus+80E
Virus+IMX
Virus+IMO
Virus+80E+MAPA
Virus+80E+MAA

FIG. 1



0h
24h
Virus titer (PFU/ml)
1000000
100000
10000
1000
100
10
1
rYFD1
rYFD2
rYFD3
rYFD4
D1+DPBS
D1+80E
D1+80E+MAA
D1+80E+IMX
D2+DBPS
D2+80E
D2+80E+MAA
D2+80E+IMX
D3+DBPS
D3+80E
D3+80E+MAA
D3+80E+IMX
D4+DBPS
D4+80E
D4+80E+MAA
D4+80E+IMX

FIG.2



0h
24h
Virus titer (PFU/ml)
1.00E+05
1.00E+04
1.00E+03
1.00E+02
1.00E+01
1.00E+00
PBS
V180
V180+1x MAA
V180+Alhydrogel
D1
PBS
V180
V180+1x MAA
V180+Alhydrogel
D2
PBS
V180
V180+1x MAA
V180+Alhydrogel
D3
PBS
V180
V180+1x MAA
V180+Alhydrogel
D4

FIG.3



0h
24h
Virus titer (PFU/ml)
1.00E+07
1.00E+06
1.00E+05
1.00E+04
1.00E+03
1.00E+02
1.00E+01
1.00E+00
rYF-DEN2+PBS
rYF-DEN2+PIV
rYF-DEN2+PIV+MAA
rYF-DEN2+PIV+Alhydrogel

FIG.4

Dengue Serotype Neutralizing Antibody Titers ($LiCor_{50}$ GMT) Induced in Rhesus Macaques at Week 4 (4 weeks post dose 1)

Group	Monkeys Per Group	Formulation/Schedule		Anti-DENV-1 $LiCor_{50}$ Titers (GMT)	Anti-DENV-2 $LiCor_{50}$ Titers (GMT)	Anti-DENV-3 $LiCor_{50}$ Titers (GMT)	Anti-DENV-4 $LiCor_{50}$ Titers (GMT)
		Week 0	Week 24				
1	4	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	48	1280	57	80
2	4	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) /MAA (225 μg) Administered IM (0.5 ml)	34	320	14	28
3	4	Tetravalent YF-DEN (10e5 pfu each) Administered IM (0.5 ml)	Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) /MAA (225 μg) Administered IM (0.5 ml)	269	1076	269	80
4	4	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / MAA (225 μg) Administered IM (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / MAA (225 μg) Administered IM (0.5 ml)	269	1076	135	95
5	4	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / ISCOMATRIX™ (30 ISCO units) Administered IM (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / ISCOMATRIX™ (30 ISCO units) Administered IM (0.5 ml)	135	1522	453	95
$LiCor_{50}$ result of <10 considered 5 for purposes of calculating GMT.							

FIG.5

Dengue Serotype Neutralizing Antibody Titers ($LiCor_{50}$ GMT) Induced in Rhesus Macaques at Week 28 (4 weeks post dose 2)

Group	Monkeys Per Group	Formulation/Schedule		Anti-DENV-1 $LiCor_{50}$ Titers (GMT)	Anti-DENV-2 $LiCor_{50}$ Titers (GMT)	Anti-DENV-3 $LiCor_{50}$ Titers (GMT)	Anti-DENV-4 $LiCor_{50}$ Titers (GMT)
		Week 0	Week 24				
1	4	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	320	320	113	48
2	4	Tetravalent YF-DEN (10e5 pfu each) Administered SC (0.5 ml)	Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) /MAA (225 μg) Administered IM (0.5 ml)	1076	1522	269	320
3	4	Tetravalent YF-DEN (10e5 pfu each) Administered IM (0.5 ml)	Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) /MAA (225 μg) Administered IM (0.5 ml)	2560	1810	905	538
4	4	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / MAA (225 μg) Administered IM (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / MAA (225 μg) Administered IM (0.5 ml)	3044	2153	905	1076
5	4	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / ISCOMATRIX™ (30 ISCO units) Administered IM (0.5 ml)	Tetravalent YF-DEN (10e5 pfu each) / Tetravalent DEN-80E (10, 10, 10, 20 μg each 80E) / ISCOMATRIX™ (30 ISCO units) Administered IM (0.5 ml)	1810	2560	1280	1076

$LiCor_{50}$ result of <10 considered 5 for purposes of calculating GMT.

FIG.6



YF-DEN (sc)
YF-DEN (sc); DEN-80E/MAA (im)
YF-DEN (im); DEN-80E/MAA (im)
Tetra YF-DEN/DEN-80E MAA (im)
Tetra YF-DEN/DEN-80E IMX (im)
Longitudinal Geometric Mean LiCor Neutralization Titers
DEN 1
DEN 2
DEN 3
DEN 4
LiCor50 Microneut. Titers
Month
10000
1000
100
10
1
0 1 2 3 4 5 6 7 8

FIG.7